Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis Diana Bilton, Gabriel Bellon, Brett Charlton, Peter Cooper,

Slides:

Advertisements

Similar presentations

Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis Giuseppe Valenza, Dennis Tappe, Doris.

Advertisements

Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Towards an individualized protocol for workload increments in cardiopulmonary exercise testing in children and adolescents with cystic fibrosis H.J.

William G. Flight, Jonathan Shaw, Susan Johnson, A

Felix Ratjen, Paul Koker, David E

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H

Patrick A. Flume, John P. Clancy, George Z. Retsch-Bogart, D

Amoxicillin–clavulanic acid resistance in fecal Enterobacteriaceae from patients with cystic fibrosis and healthy siblings Gwen Duytschaever, Geert Huys,

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

John Widger, Sarath Ranganathan, Philip J. Robinson

The ease of breathing test tracks clinical changes in cystic fibrosis

Rate of improvement of CF life expectancy exceeds that of general population— Observational death registration study Matthew N. Hurley, Tricia M. McKeever,

Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,

Controlled clinical trials in cystic fibrosis — are we doing better?

Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state Bradley.

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Cystic fibrosis mortality trend in Italy from 1970 to 2011

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation.

The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation Verena I. Seliger, David Rodman, Fredrick Van.

Amyloidosis in cystic fibrosis: A case series

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Effect of supervised training on FEV1 in cystic fibrosis: A randomised controlled trial Susi Kriemler, Stephanie Kieser, Sibylle Junge, Manfred Ballmann,

Pulmonary nocardiosis in cystic fibrosis

A.H. Gifford Journal of Cystic Fibrosis

Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis Elizabeth F. Shead, Charles S. Haworth,

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Inhalation solutions — Which ones may be mixed

Physiologic endpoints for clinical studies for cystic fibrosis

Valerie Waters, Eshetu G

Cytokine gene polymorphisms and severity of CF lung disease

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis M.N. Hurley, A.H. Amin Ariff, C. Bertenshaw,

C. Van de Kerkhove, P. C. Goeminne, M. Kicinski, T. S. Nawrot, N

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis C. Calabrese, A. Tosco, P. Abete, V. Carnovale,

Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis Giuseppe Valenza, Dennis Tappe, Doris.

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

V. Terlizzi, A. Tosco, R. Tomaiuolo, A. Sepe, N. Amato, A. Casale, C

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate.

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J

Predictors of non-referral of patients with cystic fibrosisfor lung transplant evaluation in the United States Kathleen J. Ramos, Bradley S. Quon, Kevin.

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Patients with cystic fibrosis and normoglycemia exhibit diabetic glucose tolerance during pulmonary exacerbation Noa Nezer M. Sc, David Shoseyov, Eitan.

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa C.E. Wainwright, A.L. Quittner, D.E.

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005 Donald R. VanDevanter, Eric P. Elkin,

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Cystic fibrosis and pregnancy in the modern era: A case control study

Presentation transcript:

Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis Diana Bilton, Gabriel Bellon, Brett Charlton, Peter Cooper, Kris De Boeck, Patrick A. Flume, Howard G. Fox, Charles G. Gallagher, David E. Geller, Eric G. Haarman, Helge U. Hebestreit, John Kolbe, Allen Lapey, Phil Robinson, Jian Wu, Jonathan B. Zuckerman, Moira L. Aitken Journal of Cystic Fibrosis Volume 12, Issue 4, Pages 367-376 (July 2013) DOI: 10.1016/j.jcf.2012.11.002 Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Flow-chart of the study. Journal of Cystic Fibrosis 2013 12, 367-376DOI: (10.1016/j.jcf.2012.11.002) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Mean absolute (mL) change from baseline in FEV1 — ITT population. Journal of Cystic Fibrosis 2013 12, 367-376DOI: (10.1016/j.jcf.2012.11.002) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 % Change from baseline in % FEV1 predicted by age — ITT population. Journal of Cystic Fibrosis 2013 12, 367-376DOI: (10.1016/j.jcf.2012.11.002) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 4 a. Forest plot of FEV1 % change of % predicted. b. Forest plot of FVC % change of % predicted. Journal of Cystic Fibrosis 2013 12, 367-376DOI: (10.1016/j.jcf.2012.11.002) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 5 a. Relative risk for protocol defined pulmonary exacerbation by subgroups — ITT population. b. Time to first protocol defined pulmonary exacerbation — ITT population. Journal of Cystic Fibrosis 2013 12, 367-376DOI: (10.1016/j.jcf.2012.11.002) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions